Scientists from the H. Lee Moffitt Cancer Center and Research Institute (USA) have discovered that the process of necroptosis (programmed cell death) can hinder successful cancer treatment. Research results It was published In the journal Cancer Cell.
In the scientific community, necroptosis is generally considered a way to enhance the immune response. However, new evidence shows that the cell’s self-destruct mechanism may pose certain risks. It turns out that during necroptosis, cancer cells release a molecule called interleukin-1α, which helps the tumor survive and suppresses the activity of T cells, key elements of the immune system.
Scientists conducted a series of experiments using animal models and data from patients to investigate how necroptosis affects the tumor environment. It turns out that interleukin-1α is released not only during necroptosis but also in response to chemotherapy; This may explain the partial ineffectiveness of standard treatments.
In experiments, researchers were able to activate the immune response by blocking the action of interleukin-1α and significantly increase the effectiveness of both chemotherapy and immunotherapy. In addition, better treatment results were obtained in patients with low interleukin-1α levels.
This finding highlights the importance of interleukin-1α as a potential marker to evaluate the effectiveness of treatment and choose a personalized treatment approach. The new data paves the way for the development of methods that will help eliminate the negative effects of necroptosis and improve cancer treatment outcomes.
Scientists’ work gives hope for the creation of more effective strategies to combat cancer, based on a deeper understanding of the mechanisms that interfere with cancer treatment.
Previous scientists was discovered “Dark genes” in human DNA.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.